These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22087819)

  • 1. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
    Ferrarini M; Ferrero E
    Curr Med Chem; 2011; 18(34):5185-95. PubMed ID: 22087819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapeutic approaches in multiple myeloma.
    Ribatti D; Mangialardi G; Vacca A
    Curr Cancer Drug Targets; 2012 Sep; 12(7):768-75. PubMed ID: 22780844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Insights in Anti-Angiogenesis in Multiple Myeloma.
    Ribatti D; Vacca A
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30002349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tumour angiogenesis in haematological malignancies.
    Medinger M; Passweg J
    Swiss Med Wkly; 2014; 144():w14050. PubMed ID: 25375891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
    Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
    Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-myeloma agents and angiogenesis.
    Anargyrou K; Dimopoulos MA; Sezer O; Terpos E
    Leuk Lymphoma; 2008 Apr; 49(4):677-89. PubMed ID: 18398734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
    Zarfati M; Avivi I; Brenner B; Katz T; Aharon A
    Angiogenesis; 2019 Feb; 22(1):185-196. PubMed ID: 30386953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of antiangiogenic effect in multiple myeloma treatment.
    Barchnicka A; Olejniczak-Nowakowska M; Krupa-Kotara K; Grosicki S
    Adv Clin Exp Med; 2018 Feb; 27(2):291-297. PubMed ID: 29521075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.
    Eleutherakis-Papaiakovou V; Karali M; Kokkonouzis I; Tiliakos I; Dimopoulos MA
    Leuk Lymphoma; 2003 Jun; 44(6):937-48. PubMed ID: 12854891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for treatment of multiple myeloma.
    Bruno B; Rotta M; Giaccone L; Massaia M; Bertola A; Palumbo A; Boccadoro M
    Lancet Oncol; 2004 Jul; 5(7):430-42. PubMed ID: 15231250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging biological insights and novel treatment strategies in multiple myeloma.
    Gentile M; Recchia AG; Mazzone C; Morabito F
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Anderson KC
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in multiple myeloma.
    Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulation of multiple myeloma.
    Tohnya TM; Figg WD
    Cancer Biol Ther; 2004 Nov; 3(11):1060-1. PubMed ID: 15640623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in hematologic malignancies and its clinical implications.
    Yang R; Han ZC
    Int J Hematol; 2002 Apr; 75(3):246-56. PubMed ID: 11999351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
    Bianchi G; Ghobrial IM
    Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.